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Background: CHD8 haploinsufficiency causes autism and macrocephaly with high 5 
penetrance in the human population. Chd8 heterozygous mice exhibit relatively subtle brain 6 
overgrowth and little gene expression changes in the embryonic neocortex. The purpose of this 7 
study was to generate new, sub-haploinsufficient Chd8 mouse models to allow us to identify 8 
and study the functions of CHD8 during embryonic cortical development. 9 
Methods: To examine the possibility that certain phenotypes may only appear at sub-10 
heterozygous Chd8 levels in the mouse, we created an allelic series of Chd8-deficient mice to 11 
reduce CHD8 protein levels to approximately 35% (mild hypomorph), 10% (severe 12 
hypomorph) and 0% (neural-specific conditional knockout) of wildtype levels. We used RNA 13 
sequencing to compare transcriptional dysregulation, structural MRI and brain weight to 14 
investigate effects on brain size, and cell proliferation, differentiation and apoptosis markers in 15 
immunostaining assays to quantify changes in neural progenitor fate. 16 
Results: Mild Chd8 hypomorphs displayed significant postnatal lethality, with surviving 17 
animals exhibiting more pronounced brain hyperplasia than heterozygotes. Over 2000 genes 18 
were dysregulated in mild hypomorphs, including autism-associated neurodevelopmental and 19 
cell cycle genes. We identify increased proliferation of non-ventricular zone TBR2+ 20 
intermediate progenitors as one potential cause of brain hyperplasia in these mutants. Severe 21 
Chd8 hypomorphs displayed even greater transcriptional dysregulation, including evidence for 22 
p53 pathway dysregulation. In contrast to mild hypomorphs, these mice displayed reduced 23 
brain size and increased apoptosis in the embryonic neocortex. Homozygous, conditional 24 
 3 
deletion of Chd8 in early neuronal progenitors resulted in pronounced brain hypoplasia, partly 1 
caused by pronounced p53 target gene derepression and apoptosis in the embryonic neocortex.  2 
Limitations: Our findings identify an important role for the autism-associated factor CHD8 in 3 
controlling the proliferation of intermediate progenitors in the mouse neocortex. We propose 4 
that CHD8 has a similar function in human brain development, but studies on human cells are 5 
required to confirm this. Because many of our mouse mutants with reduced CHD8 function die 6 
shortly after birth, it is not possible to fully determine to what extent reduced CHD8 function 7 
results in autism-associated behaviours in mice. 8 
Conclusions: Together, these findings identify important, dosage-sensitive functions for 9 
CHD8 in p53 pathway repression, neurodevelopmental gene expression and neural progenitor 10 
fate in the embryonic neocortex. We conclude that brain development is acutely sensitive to 11 
reduced CHD8 expression and that the varying sensitivities of different progenitor populations 12 
and cellular processes to CHD8 dosage result in non-linear effects on gene transcription and 13 




  18 
 4 
Background 1 
Mutations in CHD8 (Chromodomain helicase DNA-binding protein 8) are some of the highest 2 
confidence risk factors for autism spectrum disorder (ASD) identified to date (1-5), with 96% 3 
of individuals with CHD8 mutations presenting with autism, and 64% with macrocephaly  (6, 4 
7).  5 
 6 
CHD8 encodes a member of the ATP-dependent CHD chromatin remodelling family (8) and 7 
was initially identified as a direct repressor of β-catenin and p53 target genes (9-12). Early 8 
embryonic lethality of homozygous Chd8 deletion in the mouse is associated with p53-9 
mediated apoptosis, consistent with its role as a transcriptional repressor of p53 target genes 10 
(11). By contrast, CHD8 is typically recruited to promoters enriched for transcriptionally-11 
permissive chromatin marks in neural progenitors, suggesting a role for CHD8 in 12 
transcriptional activation (13, 14). Indeed, ASD-associated genes were downregulated in 13 
neural progenitor cells upon CHD8 knockdown (13, 14). Evidence for mild brain overgrowth, 14 
reminiscent of the macrocephaly observed in patients with CHD8 mutations, has been reported 15 
in several different Chd8 heterozygous mouse models (15-18) Jimenez ref.  16 
 17 
To explore the transcriptional dysregulation that may underlie abnormal brain development in 18 
heterozygous mice, gene expression has been investigated at different stages of brain 19 
development. These studies have revealed subtle gene expression changes in Chd8+/- mice 20 
during embryonic development (15, 17-19). By contrast, in vitro studies on neural progenitor 21 
cells have identified more substantial transcriptional dysregulation arising from CHD8 knock-22 
down. For instance, Sugathan et al. observed 1756 differentially expressed genes (DEGs) upon 23 
CHD8 knock-down in human iPSC-derived neural progenitor cells (14). Gene expression 24 
 5 
changes in Chd8+/- mice also appear to be strongly influenced by developmental stage, with 1 
more extensive transcriptional changes observed at peri- and postnatal stages (17, 18). 2 
 3 
The striking phenotypes associated with human CHD8 mutations and pronounced gene 4 
expression changes in neural progenitor cell lines upon CHD8 knockdown, contrast with the 5 
mild brain and embryonic transcriptional abnormalities observed in Chd8 heterozygous mice. 6 
The only study so far to report convincing ASD-like behavioural phenotypes associated with 7 
Chd8 deficiency, involved Chd8 knock-down to ~20% of wildtype protein levels by selective 8 
in utero electroporation of neuronal progenitors contributing to upper layer neurons (20). 9 
Together, these findings suggest that CHD8 haploinsufficiency may have more pronounced 10 
effects on human brain development, or that some human ASD-associated mutations may 11 
reduce CHD8 function by more than 50%. 12 
 13 
To examine the possibility that certain phenotypes may only appear at sub-heterozygous Chd8 14 
levels in the mouse, we created an allelic series of Chd8-deficient mice to reduce CHD8 protein 15 
gradually to approximately 35% (mild hypomorph), 10% (severe hypomorph) and 0% 16 
(conditional knockout) of wildtype levels. Non-monotonic effects on brain growth were 17 
observed, with mild hypomorphs exhibiting increased brain size, and severe hypomorphs and 18 
conditional knockout mice smaller brain size.  We found that increased brain size in mild 19 
hypomorphs was associated with increased proliferation of TBR2+ intermediate progenitors. 20 
As this cell type contributes to increased human brain expansion during evolution (21), this 21 
finding suggests that CHD8 may have more pronounced effects on human brain development. 22 
We conclude that reducing CHD8 function below 50% have disproportionally large, and non-23 
linear effects on gene expression and brain development. 24 





A transgenic mouse line containing a Chd8neo allele (Chd8tm1.Mabn) was generated as reported 4 
previously (18). Briefly, an 18.8 kb targeting construct was generated consisting of a 14.84kb 5 
genomic DNA fragment subcloned from a C57BL/6 BAC clone (RP23:318M20) with an added 6 
loxP/FRT-PGK-gb2-Neo cassette 3’ of exon 3 (ingenious Targeting Laboratory (iTL), 7 
Ronkonkoma, NY, USA) and additional loxP site 5’ of exon 3 (Fig. 1). The targeting construct 8 
was linearised and electroporated in C57BL/6J ES cells. Five clones were identified with 9 
successful recombination, two of which (124 and 254) were injected into Balb/c blastocysts. 10 
Resulting chimaeras were backcrossed onto a C57BL/6J background to generate Chd8neo/+ 11 
mice. Experimental Chd8neo/neo mice were produced by Chd8neo/+ x Chd8neo/+ crosses. To 12 
generate a conditional Chd8 allele (Chd8flox (Chd8tm1.1Mabn)), Chd8neo/+ mice were crossed with 13 
Flpe deleter mice on a C57BL/6J background (Fig. 1). Chd8flox/+ mice were then either inter-14 
crossed to obtain a homozygous Chd8flox/flox line or with Sox1-Cre (22) to generate Sox1-Cre; 15 
Chd8flox/+ mice. To produce pan-neuronal Chd8 null (conditional knockout, cKO) mice, Sox1-16 
Cre; Chd8flox/+ mice were mated with Chd8flox/flox mice. Sox1-Cre; Chd8flox/flox cKO embryos 17 
were compared with Sox1-Cre; Chd8flox/+ (cHET) and Chd8flox/flox (Ctrl) embryos. To generate 18 
conditional p53-heterozygotes, mice carrying the Trp53tm1Brn conditional (p53flox) allele were 19 
obtained from the Jackson laboratories (23) and crossed to the Chd8 conditional mice. 20 
Chd8flox/+ mice were also bred with b-actinCre mice (24) to generate a Chd8 null (Chd8-, 21 
(Chd8tm1.2Mabn)) allele. b-actinCre;Chd8+/- mice were then crossed with C57BL/6J mice to 22 
remove the Cre transgene and establish a Chd8+/- line. Chd8+/- mice were produced by Chd8+/- 23 
x C57BL/6J crosses, taking care to equalise paternal or maternal inheritance of the Chd8 null 24 
allele. Experimental Chd8neo/- mice were produced by Chd8neo/+ x Chd8+/- crosses. In 25 
 7 
experiments comparing different genotypes, replicate samples were from different litters to 1 
avoid litter-specific effects. All animal procedures were approved by the UK Home Office. 2 
 3 
Genotyping of mice 4 
Genomic DNA was extracted for genotyping from ear samples (or yolk sac for embryos aged 5 
E14.5 and below) using Proteinase K digestion or the HotSHOT method (25). Genotyping 6 
reactions were then performed for the presence of Chd8 wildtype, null or floxed alleles, p53 7 
wildtype or floxed alleles, as well as the presence of Cre. Thermal cycles for all genotyping 8 
reactions were as follows: 94oC, 5 minutes; 35X (94oC, 30sec; 58oC, 30sec; 72oC, 30sec); 72oC, 9 
5 minutes. Primer pairs to amplify a sequence distinguishing between Chd8flox,Chd8neo and 10 
wildtype alleles (‘Chd8flox’ primers, 212bp and 275bp product for mutant or wildtype, 11 
respectively), to detect the presence of the Chd8null allele (‘Chd8null’ primers, 395bp), to 12 
distinguish between p53 floxed and wildtype alleles (‘p53flox’ primers, 390bps and 270bps, 13 
respectively) and primers to amplify a specific Cre sequence (‘Cre’ primers, 390bp product) 14 
were used as listed in Suppl. Table 5. 15 
 16 
RNA extraction and qRT-PCR analysis 17 
Cortical RNA was extracted by lysing cortices in 600µl Trizol (Life Technologies). After 18 
purification, RNA was DNase treated using the Direct-zol RNA MiniPrep kit (Zymo Research) 19 
according to the manufacturer’s recommendations. cDNA was synthesised for qRT-PCR 20 
experiments using 50ng RNA from 4 biological replicates per condition with the Precision 21 
nanoScript 2 Reverse Transcription Kit (PrimerDesign Ltd.) according to the manufacturer’s 22 
instructions. qRT-PCRs were performed on a Stratagene Mx3000p (Agilent Technologies) 23 
using PrecisionPlus-MX 2x qPCR Mastermix with SYBR green (PrimerDesign Ltd.) and 24 
primers against Atm, Atr, Trp53, Cdkn1a, Ccng1, Mdm2, Chd8, and Pmaip1. Relative 25 
 8 
expression levels were calculated using the 2-∆∆CT method and Gapdh and Ywhaz were used as 1 
endogenous control genes. 2 
 3 
Western blot 4 
Telencephalic vesicles were dissected from E12.5 embryos and whole cell protein prepared by 5 
lysing in 8M urea, 1% CHAPS, 50mM Tris (pH 7.9) lysis buffer containing protease inhibitors 6 
(PMSF, Pepstatin A, Leupeptin, Aprotinin; Roche) and a phosphatase inhibitor cocktail 7 
(Sigma). After rotating at 4°C for 30 mins, DNA was removed from lysates by centrifugation. 8 
Supernatant was transferred to a fresh tube and stored at -80°C. Protein loading samples were 9 
made by diluting samples in Laemmli buffer containing 10% β-mercaptoethanol, followed by 10 
boiling at 100°C for 10 minutes. Samples were loaded (10µg total protein per lane) onto a 11 
Mini-PROTEAN pre-cast gel (Bio-Rad) and resolved using gel electrophoresis. Protein was 12 
transferred to a nitrocellulose membrane (Bio-Rad), which was then blocked in 5% non-fat 13 
milk powder (Bio-Rad) and 1% bovine serum albumin (BSA, Sigma) in TBS with 0.1% 14 
Tween-20 (TBST) for one hour at room temperature. Where β-actin was used as a loading 15 
control, the membrane was then cut in two: the higher molecular weight section was incubated 16 
with anti-CHD8 primary antibody (rabbit anti-CHD8 N-terminal, Bethyl Laboratories, 1/2000) 17 
and the lower molecular weight section incubated with anti-β-actin antibody (rabbit anti-β-18 
actin, Abcam, 1/4000); both antibodies in 3% non-fat milk powder and 1% BSA in TBST 19 
overnight at 4°C. After washing, membrane was incubated with HRP-conjugated secondary 20 
antibody (Millipore) for one hour at room temperature. HRP was detected with Clarity ECL 21 
reagent (Bio-Rad) and the membrane imaged using a Bio-Rad ChemiDoc system. Where 22 
GAPDH was used as a loading control, the uncut membrane was washed in TBST after 23 
detection of CHD8 protein and incubated overnight at 4°C in 0.05% sodium azide in PBS, 24 
before washing and incubation with anti-GAPDH primary antibody (rabbit anti-GAPDH, 25 
 9 
Abcam, 1/40000) overnight at 4°C. Membrane was probed with HRP-conjugate and imaged as 1 
before. Raw proteins levels were quantified using Bio-Rad ImageLab software. All replicates 2 
on each given blot were first normalised to their respective GAPDH loading controls. Where 3 
the same samples were run across multiple blots their normalised values were averaged across 4 
all blots and this value used for statistical analysis. Normalised values for all samples were 5 
compared by ANOVA to identify statistically significant differences between the different 6 
genotypes. 7 
 8 
Structural MRI 9 
Mice were terminally anaesthetised and intracardially perfused as described previously (18). 10 
Voxelwise comparisons were made between mutants and all wildtypes taken from both the 11 
Chd8+/- and Chd8neo/neo batches. As wildtype brain sizes differed slightly between the two 12 
groups due to slightly different age at analysis, Chd8neo/neo data were first normalised (beta-13 
corrected) to wildtypes in the Chd8+/- batch before analysis. Voxelwise comparisons were then 14 
made between mutants and all wildtypes, and multiple comparisons in this study were 15 
controlled for using the False Discovery Rate (26). 16 
 17 
Behavioural assessments 18 
Mice for behavioural testing were maintained as described previously (18).  Housing and test 19 
rooms were kept at constant temperature (21°C) and humidity (45%) and maintained under a 20 
regular light/dark schedule with lights on from 07:30 to 19:30 hours (light = 270 lux). All mice 21 
used in behavioural assessments were housed and tested at the same facility at King’s College 22 
London. 23 
 24 
Different batches of Chd8neo/neo mice were used for (i) recording pup ultrasonic vocalisations 25 
 10 
(USVs) and spontaneous movements, followed by tests for adult behaviours and (ii and iii) 1 
adult behaviours. For the first Chd8neo/neo batch (i), tests were carried out in the following order: 2 
ultrasonic vocalisations (P2-P12), self-grooming (8-10 weeks), open field (9-11 weeks), adult 3 
social investigation (9-11 weeks), three-chamber social approach (9-11 weeks) and olfactory 4 
habituation/dishabituation (10-12 weeks). For the other two batches (ii and iii), tests were 5 
carried out as follows: rotarod (8-10 weeks), self-grooming (9-11 weeks), open field (10-12 6 
weeks), adult social investigation (10-12 weeks), marble burying (11-13 weeks), 3 chamber 7 
social approach (11-13 weeks) and olfactory habituation/dishabituation (12-14 weeks). The 8 
final batch was then further assessed using the running-wheel test (16-20 weeks). Data from 9 
different batches did not differ significantly and were all combined for analysis. 10 
 11 
One week before performing the rotarod test, mice were singly-housed to avoid any potential 12 
confounds from social and aggressive behaviour hierarchies, which could influence the 13 
controlled assessment of social behaviours (27). Sawdust was changed every other week but 14 
never on the day before, or the day of testing. The enrichment (nesting material and house) was 15 
changed less regularly to minimize the disruption to the animals. For all social tests, conspecific 16 
mice were housed in a separate room to the test mice to ensure the conspecifics were unfamiliar 17 
to the test mice. Test mice were never exposed to the same conspecific during testing to ensure 18 
novelty.  19 
 20 
Behavioural experiments were conducted between 08:30 and 18:30 in sound-proofed rooms 21 
under standard room lighting unless stated otherwise. Behaviours were recorded using a 22 
camera positioned above the test arenas and movement of each mouse tracked using 23 
EthoVision (Noldus Information Technologies, bv Wageningen, The Netherlands). Social 24 
investigation, olfaction and grooming were scored manually using MATLAB 2016b (The 25 
 11 
MathWorks, Inc., Natick, Massachusetts, USA). After each individual trial of a specific test, 1 
boli and urine were removed from the test arena which was cleaned with 1% Anistel® solution 2 
(high level surface disinfectant, Trisel Solution Ltd, Cambridgeshire, UK) to remove any odors. 3 
Experimenters were blind to the genotype of the animals both during the testing and subsequent 4 
scoring of the recorded behaviours. 5 
 6 
RNA Sequencing 7 
For RNA-sequencing at E10.5, total RNA from 2 embryos was pooled for each biological 8 
replicate (n=3 per condition). No pooling was performed at E12.5 (n=3 per condition). mRNA 9 
was isolated and reverse transcribed into cDNA. cDNA was end-repaired, adaptor-ligated and 10 
A-tailed. Paired-end sequencing (75bp read length) was performed on the Illumina HiSeq 4000 11 
platform. Quality of the raw sequencing data was checked using FastQC version 0.11.2 and 12 
trimming of adaptor sequences was performed using Trim Galore! version 0.4.1 (28) . Reads 13 
were aligned to the mouse genome (GRCm38.p4) using Tophat version 2.1.0 and aligned reads 14 
were counted using FeatureCounts version 1.5.0 (29, 30). Differential expression testing was 15 
performed using DESeq2 version 1.10.1, as previously described (31). Gene ontology analysis 16 
and functional classification was performed using DAVID with all detected DEGs below a 17 
0.05FDR (32). For heatmaps, data were transformed with a variance stabilising transformation, 18 
scaled and clustered with the Ward.d2 method using maximum distance, and plotted with the 19 
R package pheatmap version 1.0.8. The R package ggplot2 version 2.1.0 was used to generate 20 
volcano plots and DESeq2 was used to generate normalised read count plots for individual 21 
genes. The list of ASD associated genes used for overlap with the neo/neo DEGs was obtained 22 
from the SFARI Human Gene database (https://gene.sfari.org/autdb/HG_Home.do). RNA-seq 23 
data have been deposited into GEO, accession number GSE81103. 24 
 25 
 12 
Tissue collection and processing 1 
Embryos were collected and brains dissected from the skulls in ice-cold PBS for E18.5 2 
embryos. Wholemount pictures were taken on a Nikon SMZ1500 stereomicroscope equipped 3 
with a Nikon DS-Fi1 camera head, followed by post-fixation in 4% PFA for 24h at 4°C. For 4 
BrdU experiments, pregnant mothers (day 13 or 15 of gestation) were injected with 40mg/kg 5 
BrdU in 0.9% saline 1 hour prior to embryo collection. After fixing, embryos were dehydrated 6 
and paraffin embedded. Paraffin blocks were then cut into 10µm (cKO and cKO;p53-het 7 
embryos) or 5µm (Chd8+/-, Chd8neo/neo and Chd8neo/- embryos) thick coronal sections and 8 
mounted. 9 
 10 
X-gal staining 11 
E9.5 embryos were collected and dissected in ice-cold PBS and post-fixed in 4% PFA for 10 12 
minutes. Following three washes in PBS (5 minutes each), embryos were incubated in X-Gal 13 
staining solution (10mM TRIS-HCL, pH7.3, 0.005% Na-deoxycholate, 0.01% IGEPAL, 5mM 14 
potassium ferrocyanide, 5mM potassium ferricyanide, 2mM MgCl2, 0.8mg/ml X-Gal, in PBS) 15 
at room temperature until adequate signal was observed. Reactions were stopped by washing 16 
in PBS (3 x 5 minutes) followed by post-fixation in 4% PFA for 1h. Control embryos never 17 
showed any staining. 18 
 19 
Immunohistochemistry and Immunofluorescence 20 
Coronal brain sections were re-hydrated using standard protocols. Antigen retrieval was 21 
conducted by heating slides in 10mM Sodium Citrate solution (pH6) for 20mins and cooled on 22 
ice. For non-fluorescence immunohistochemistry, endogenous peroxidases were blocked by 23 
incubating in 3% H2O2 and 10% MeOH in PBS for 15mins. Sections were then washed in 0.2% 24 
Triton X-100 (Sigma-Aldrich) in PBS (PBT2) for 5 mins and blocked using 10% heat-25 
 13 
inactivated normal goat serum (GS) and 2% gelatin in PBT2 for 1 hour. Sections were 1 
incubated in 5% GS in PBT2 containing primary antibody overnight at 4°C. The following 2 
antibodies were used: mouse anti-BrdU (BD Biosciences, 1/100), rabbit anti-phosphohistone 3 
3B (Cell Signaling, 1/100), mouse anti-phosphohistone 3B (Abcam, 1/200), chicken anti-4 
TBR2 (Merck Millipore, 1/200), rabbit anti-cleaved-caspase 3 (Cell Signaling, 1/200), rabbit 5 
anti-doublecortin (Abcam, 1/400) or rabbit anti-CHD8 (Bethyl, 225A, 1/400).  For 6 
immunofluorescence, sections were incubated with secondary antibody diluted in 5% GS in 7 
PBT2 for 90mins at 4°C. Secondary antibodies used included goat anti-chicken AlexaFluor 8 
488 (Invitrogen, 1/200), goat anti-mouse AlexaFluor 405 (Invitrogen, 1/200), goat anti-mouse 9 
AlexaFluor 594 (Invitrogen, 1/200), goat anti-rabbit AlexaFluor 488 (Invitrogen 1/200), goat 10 
anti-rabbit AlexFluor 568 (Invitrogen, 1/200) and donkey anti-rabbit AlexaFluor 488 11 
(Invitrogen, 1/200). Sections were counterstained using Hoechst 33342 solution (Invitrogen, 12 
1/50,000) in PBS and covered with coverslips using CitiFluor (CitiFluor Ltd., UK). For 13 
diaminobenzidine (DAB) immunohistochemistry, after incubation with primary antibody, 14 
sections were incubated in biotinylated anti-rabbit immunoglobulin secondary antibody (Dako, 15 
1/200) in 5% GS in PBT2. Samples were washed in PBS and incubated with Avidin/biotin 16 
complex (ABC, Vector) in PBS for 1 hour. Sections were developed using 0.03% DAB and 17 
0.0003% H2O2 in PBS for 10mins before washing in running water and counterstaining using 18 
Ehrlich’s Haemotoxylin solution. Slides were mounted onto coverslips using DPX (Sigma-19 
Aldrich). Images were acquired on a Nikon 80i microscope equipped with a Hamamatsu C4742 20 
CCD or Nikon 5M pixel Nikon DS digital cameras. Images were processed using Adobe 21 
Photoshop and Illustrator. 22 
 23 
Fluorescence-activated cell sorting (FACS) and qRT-PCR 24 
Pregnant females were sacrificed by cervical dislocation on embryonic day 14.5 (E14.5) and 25 
 14 
embryos were dissected out and placed in ice cold Hibernate-E solution supplemented with 1 
B27. The brain was dissected out from each embryo and the cortex removed. Cortices were 2 
maintained in ice-cold Hibernate-E/B27 whilst embryos were genotyped after which cortices 3 
with corresponding genotypes were pooled together in digest solution (0.25% Trypsin, 0.01% 4 
DNase, 10 mM HEPES in HBSS) preheated to 37oC. Cortices were incubated in digest solution 5 
for 10 minutes and washed in HBSS + 0.01% DNase to inactivate trypsin. Single-cell 6 
suspension was achieved through mechanical dissociation by gentle pipetting. Cells were 7 
washed and resuspended with PBS, incubated on ice and in the dark for 30 minutes with 1 µl 8 
of the near-IR fluorescent reactive dye from the LIVE/DEAD fixable dead cell stain kit 9 
ThermoFisher). Cells were washed once with PBS, strained into fixing solution (1.6% PFA 10 
and 0.1% saponin in molecular-grade PBS) supplemented with 1% RNasin Plus RNAse 11 
inhibitor and incubated on ice for 30 mins. Cells were washed twice with wash solution (0.2% 12 
BSA, 0.1% saponin, 0.1% RNasin Plus in molecular-grade PBS) before antibody staining. The 13 
following primary antibodies were used: phycoerythrin (PE)-conjugated mouse anti-PAX6 (sc-14 
81649, Santa Cruz Biotechnology) and chicken anti-TBR2 (AB15894, Merck Millipore). Cells 15 
were suspended in staining solution (1% BSA, 0.1% saponin, 1% RNasin Plus in molecular-16 
grade PBS) containing primary antibodies at a 1:1000 dilution and incubated on ice for 30 17 
minutes. Cells were washed twice with wash solution then suspended in staining solution 18 
containing anti-chicken AlexaFluor 488 secondary antibody (A-11039, ThermoFisher) at a 19 
1:1000 dilution. Cells were washed twice with wash solution then strained and resuspended in 20 
sorting buffer (3% BSA and 2 mM EDTA in molecular grade PBS). Fluorescence-activated 21 
cell sorting (FACS) was performed using a FACSAria III machine (BD). Samples stained 22 
individually for TBR2 and PAX6 were used as compensation controls. Debris was excluded 23 
from samples by gating on a forward and side scatter area plot and doublets excluded by gating 24 
on a plot of side scatter area by side scatter width. The LIVE/DEAD marker was detected in 25 
 15 
the APC-Cy7 channel. Any cells showing greater fluorescence intensity than an unstained 1 
control sample were considered dead and excluded. The unstained sample was also used to set 2 
a double negative gate on a PE by FITC fluorescence intensity plot. The PAX6+ gate was 3 
placed based on increased PE fluorescence and the TBR2+ gate placed based on increased 4 
FITC fluorescence. Selection gates were placed towards the extreme ends of the cell population 5 
to ensure the sorting of single positive cells only. Cells falling within the PAX6+ or TBR2+ 6 
gates were sorted and collected in sorting buffer. Cells were then pelleted, snap frozen in liquid 7 
nitrogen and stored at -80oC. RNA was extracted from sorted cell samples using the RecoverAll 8 
Total Nucleic Acid isolation kit (Life technologies) using the RNA isolation protocol with an 9 
adapted protease treatment for 3 hours at 50oC to maximise RNA yield. RNA concentration 10 
was determined with a NanoDrop 2000 (ThermoFisher). Typically, samples yielded 11 
approximately 120 ng of RNA which was stored at -80oC. Reverse transcription was performed 12 
using the Precision nanoScript2 Reverse Transcription Kit (Primerdesign) according to the 13 
manufacturer’s instructions using random nonamer primers. 60 ng of RNA was reverse 14 
transcribed for all samples and resulting complementary DNA (cDNA) stored at -20oC. qPCRs 15 
were performed using Luna Universal qPCR Master Mix (New England Biolabs). Samples of 16 
3.75 ng cDNA were run in triplicate for each primer pair using a Lightcycler 480 (Roche) and 17 
fold expression changes were calculated using the 2-ΔΔCT method. Primer sequences are given 18 
in Suppl. Table 5. 19 
 20 
Quantification and statistical analysis 21 
General 22 
Data are reported as Mean±SEM and graphs show all individual data points where feasible. 23 
Significant p-values are reported in the results section and figure legends provide details of 24 
relevant statistical parameters, including group sizes. Statistical analyses were performed either 25 
 16 
with SPSS (Version 22, IBM, Armonk, USA) or GraphPad Prism (Version 6, GraphPad 1 
Software, La Jolla, California, USA). All analyses were performed blind to genotype. 2 
RNAseq 3 
Processing of raw data and differential expression testing is described in the methods section. 4 
Multiple comparisons were controlled for using an FDR<0.05. Exact p-values and FDR 5 
adjusted p-values for all differentially expressed genes are listed in Supplementary Tables 3 & 6 
5.  7 
Cell marker quantification 8 
Proliferation 9 
Proliferation was quantified by counting either ventricular or non-ventricular phosphohistone 10 
3B-positive cells and normalising cel counts to the length of ventricular surface. Cells were 11 
counted in sections located between A-P positions 219-236 of the E14.5 Allen brain reference 12 
atlas for coronal sections (https://developingmouse.brain-13 
map.org/experiment/thumbnails/100074513?image_type=hp_yellow) and from the boundary 14 
with the eminences up to the "apex" of the neocortex in the M-L axis. Normalised counts were 15 
averaged across both hemispheres for at least three sections to give the number of 16 
phosphohistone 3B-positive cells per μm of ventricular surface in the dorsal cortex of each 17 
embryo. To determine the molecular identity of non-ventricular PH3B+ cells at E14.5, sections 18 
were co-stained for TBR2 and the number of TBR2/PH3B double-positive cells counted and 19 
normalised to ventricular surface length.  20 
 21 
Apoptosis 22 
Cleaved Caspase 3 (CC3) positive cells were counted in the E14.5 neocortex and normalised 23 
to ventricular zone length in each hemisphere as described above. Counts were averaged across 24 
 17 
both hemispheres and across a minimum of three sections per biological replicate. In E12.5 1 
cKO embryos, CC3-positive cells were counted in 50μm x 50μm boxes. Three boxes were 2 
counted for both inner (ventricular side) and outer (pial side) regions of the dorsal cortex to 3 
generate an average number of CC3-positive cells per μm2 for both inner and outer cortical 4 
regions, which were then averaged to provide the overall mean of CC3-positive cells per μm2. 5 
These were calculated for both sides of the brain individually in at least two sections per 6 
biological replicate. Apoptosis in the ventral cortex was quantified by counting CC3+ cells 7 
either in three 0.1mm x 0.1mm boxes in both lateral ganglionic eminences and three 0.15mm 8 
x 0.15mm boxes in both medial ganglionic eminences (WT and cHet), or three 0.1mm x 0.1mm 9 
boxes placed at equivalent positions across the ventral cortex (cKO and cKO-p53Het) and 10 
counts averaged for each section. These were calculated for both sides of the brain individually 11 
in at least two sections per biological replicate. 12 
 13 
Data availability 14 
The RNAseq raw data and read counts were deposited at the Gene Expression Omnibus (GEO) 15 
archive under the accession number GSE121381. 16 
 17 
  18 
 18 
Results 1 
A Chd8 allelic series reveals non-linear effects of CHD8 deficiency on brain growth. 2 
To establish a Chd8 allelic series in the mouse, we first generated a hypomorphic Chd8 allele 3 
(Chd8neo, Fig. 1A) by inserting a neo cassette between exons 3 and 4 to reduce gene expression 4 
through splicing and termination of transcripts (33, 34). Aberrant splicing of Chd8 transcripts 5 
into the neo cassette was confirmed (Fig. 1A). Chd8neo/neo and Chd8neo/- embryos showed 85% 6 
and 88% reductions in Chd8 transcripts, respectively, compared to the 63% decrease in Chd8+/- 7 
embryos (Fig. 1B). Full-length CHD8 protein levels were reduced by approximately 50% in 8 
Chd8+/-(heterozygous), 64% in Chd8neo/neo (mild hypomorph), and 91% in Chd8neo/- (severe 9 
hypomorph) neocortices, with no evidence for remaining truncated CHD8 protein products 10 
(Fig. 1C, Suppl. Fig. 1). 11 
 12 
Chd8neo/neo mice exhibited a significant reduction in postnatal survival (Table 1). As CHD8 is 13 
expressed in multiple tissues during development (35), this postnatal lethality is likely a 14 
consequence of congenital defects affecting essential organs.  15 
 16 
Table 1: Reduced postnatal survival of Chd8neo/neo pups. 17 
 18 
























Mice were born at expected Mendelian frequencies from Chd8neo/+ intercrosses. Percentage 19 
survival is shown for the different genotypes at P0, P14 and P35. Note the significantly reduced 20 
observed percentage of homozygous Chd8neo/neo mutants at P14 and P35 (***p<0.001, Chi-21 
square test) in two independent groups of mice.  22 
 23 
 19 
High resolution structural MRI revealed volumetric increases in a number of brain regions in 1 
Chd8neo/neo mice compared to wildtype littermates (Fig. 1D).  This phenotype was more 2 
pronounced than in Chd8+/- mice (Fig. 1D), with total brain volume increased by 4.5% in 3 
Chd8neo/neo mice, compared to the 2.7% increase in Chd8+/- mice (Fig. 1E). As our Chd8+/- data 4 
were from males only, we also calculated the increase in brain volume increase in male 5 
Chd8neo/neo mice only, to exclude the possibility that female Chd8neo/neo mice were responsible 6 
for the observed increase in brain volume. The average brain volume of Chd8neo/neo male mice 7 
(n=8) were increased by 5.4% compared to their male wildtype littermates (n=14), compared 8 
to the 2.7% increase in volume of male Chd8+/- mice (n=12) compared to their male wildtype 9 
littermates (n=12). Several regions that showed evidence of overgrowth in Chd8+/- mice (Fig. 10 
1E, Table 2) demonstrated robust increases in volume in Chd8neo/neo mice, including the frontal, 11 
cingulate and entorhinal cortices and the hippocampus (Fig. 1E, Table 2, Suppl. Table 1).  12 
 13 
Table 2. Brain volume differences relative to control wildtype littermates 14 
 
Brain area 
Chd8 genotype  
+/-           neo/neo  













cortex 3.82% - 
cerebellum 3.41% 
hippocampus 5.97% - 
primary motor cortex 3.68% - 
primary somatosensory cortex 3.7% - 
primary auditory cortex 3.2% 
primary visual cortex 3.39% 
frontal cortex 3.99% - 
frontal association cortex 4.81% - 
entorhinal cortex 4.83% - 
cingulate cortex 4.57% - 
amygdala 3.82% 
 15 
-FDR<0.15; * FDR<0.05; **FDR<0.01. MRI data from Chd8+/- and littermate control mice 16 
used for comparison are from Suetterlin et al. (18). 17 
 18 
 20 
To determine the effects of reducing Chd8 levels further, we assessed postnatal survival of   1 
Chd8neo/- severe hypomorphs. Chd8+/- x Chd8neo/+ matings yielded no live Chd8neo/- animals by 2 
P7-P14 (n=0/22), indicative of a significant postnatal lethality (p<0.001; Chi-square test). To 3 
assess the phenotype of severe hypomorphs, we collected embryos at E18.5. Measuring brain 4 
weights in these embryos, revealed that Chd8neo/- brains were 13.4mg (18.3%) lighter than 5 
brains from Chd8+/+ littermates (Suppl. Fig. 2A,B,E,G). Chd8+/- brains weighed on average 6 
4.74mg (6.47%) heavier than controls (Suppl. Fig. Fig. 2C,D,F,G), in agreement with our 7 
previous report (Suetterlin et al, 2018). In addition, 50% of Chd8neo/- embryos showed 8 
unilateral anopthalmia (Suppl. Fig. 2H), in agreement with strong Chd8 expression in the 9 
developing eye (35). Taken together, these data suggested that brain growth responds to 10 
reductions in CHD8 levels in a non-linear manner, with heterozygotes and mild hypomorphs 11 
exhibiting brain overgrowth, and severe hypomorphs presenting with brain hypoplasia.  12 
 13 
Chd8neo/neo mice demonstrate mild behavioural anomalies similar to those seen in Chd8+/- 14 
mice. 15 
To explore whether behavioural phenotypes may be exacerbated in the Chd8neo/neo mild 16 
hypomorphs compared to Chd8+/- mice, we assessed socio-communicative, repetitive, anxiety 17 
and motor behaviours. In total, three batches of Chd8neo/neo mice were assessed for the same 18 
behaviours. As no batch effects and no sexually dimorphic behaviours were observed, data 19 
from all three experiments and both sexes were combined for analysis. Chd8 hypomorphs 20 
displayed normal social approach and investigation behaviours in the three-chamber (Fig. 2A) 21 
and reciprocal social investigation tests (Fig. 2B). Relative to wildtype littermates, hypomorph 22 
pups emitted normal numbers of ultrasonic vocalisations (USVs) on separation from the nest, 23 
suggesting no deficits in socio-communicative abilities (Fig. 2C). Furthermore, Chd8neo/neo 24 
mice demonstrated a normal capacity for habituation and dishabituation to both social (sex-25 
 21 
matched urine) and non-social (banana) odours (Fig. 2D). We did not observe any differences 1 
in repetitive self-grooming behaviour between hypomorphs and wildtypes (Fig. 2E). In the 2 
marble burying test, a task also designed to measure repetitive behaviours in mice, Chd8neo/neo 3 
mice buried fewer marbles than controls (Fig. 2F). Interestingly, Chd8 hypomorphs showed 4 
increased aversion towards the centre of the open field arena (Fig. 2G-H), suggesting that 5 
reduced Chd8 expression may predispose to anxiety. In addition, these mice demonstrated 6 
decreased locomotor activity in the open field arena, even when controlling for their anxiety 7 
phenotype (Fig. 2I). This hypo-active phenotype was corroborated by homecage running wheel 8 
tests (Fig. 2J) and may account for the reduced marble burying observed in these mice. 9 
However, the hypo-activity did not appear to be due to motor defects, as these mice showed 10 
motor performance comparable to controls in the rotarod test (Fig. 2K). 11 
 12 
In summary, Chd8neo/neo mice showed no evidence of socio-communicative deficits or 13 
repetitive behaviours typically associated with ASD, suggesting that the reason for a lack of 14 
robust ASD-like behaviours in Chd8-deficient mouse models is unlikely to be an insufficient 15 
reduction in Chd8 expression. The most robust, reproducible phenotype was locomotor 16 
hypoactivity, which was present in both our mild hypomorphic and Chd8+/- mice (18), and also 17 
Chd8+/- mice reported by Platt et al. (16). Intriguingly, whereas our Chd8+/- mice did not show 18 
clear anxiety phenotypes (18), the Chd8 hypomorphs did, suggesting that this particular 19 
phenotype may be enhanced by a reduction in Chd8 levels.  20 
 21 
Gradual reductions in CHD8 levels result in progressively more pronounced gene 22 
expression changes. 23 
To understand how sub-heterozygous Chd8 levels affect gene expression in the embryonic 24 
neocortex, RNA-sequencing (RNA-seq) was performed from E12.5 neocortices. Data from 25 
 22 
heterozygous (Chd8+/-), mild (Chd8neo/neo) and severe (Chd8neo/-) hypomorphs, together with 1 
their respective wildtype littermate controls were included for analysis. 2 
 3 
This analysis identified only 14 differentially expressed genes (DEGs, excluding Chd8, FDR 4 
<0.05) in Chd8+/- (Fig. 3A, Suppl. Table 2, Suppl. Fig. 3) and 2209 DEGs in Chd8neo/neo 5 
neocortices (Fig. 3B, Suppl. Table 2, Suppl. Fig. 3), indicating that many genes only show 6 
significant transcriptional effects when CHD8 levels fall below 50%. In Chd8neo/- embryos, 7 
2592 DEGs (FDR <0.05) were identified (Fig. 3C, Suppl. Table 2, Suppl. Fig. 3). The 8 
visualisation of differential gene expression in a heat map demonstrated the marked 9 
transcriptomic differences between heterozygotes and mild hypomorphs (Fig. 3D). DEGs 10 
could be divided into four groups based on their responses to reduced CHD8 levels: 1) genes 11 
that show a “linear” response to Chd8 downregulation (e.g. Tet1 and Zcwpw1, Fig. 3E, Suppl. 12 
Fig. 3C), 2) genes that are not significantly different in Chd8+/- embryos but sharply up- or 13 
downregulated in Chd8neo/neo embryos (e.g. Nlgn3 and Slc1a5, Fig. 3E, see also Suppl. Fig. 3B), 14 
3) genes that are only significantly dysregulated in Chd8neo/- embryos (e.g. Gpat2), and 4) genes 15 
that exhibited non-linear responses (e.g. Slc9b2, Fig. 3E). The majority of DEGs (>99%) fell 16 
within group 2, indicating that over 2000 genes showed a striking threshold response as CHD8 17 
protein is reduced from heterozygotes to mild hypomorphs. 18 
 19 
Comparing DEGs in Chd8neo/neo and Chd8neo/- samples identified 1389 genes common to both 20 
datasets (Fig. 3F), all of which were changed in the same direction. ASD-associated genes were 21 
highly enriched in the DEGs from both Chd8neo/neo (145 genes, p=1.32x10-9, OR = 1.83, 22 
Fisher’s exact test for count data, Fig. 3F, Suppl. Table 2) and Chd8neo/- embryos (152 genes, 23 
p= 5.532 x10-7, OR = 1.62, Fisher’s exact test for count data, Suppl. Table 2). Nearly half 24 
(46%) of these ASD-associated genes were common to Chd8neo/neo and Chd8neo/- mice (Fig. 25 
 23 
3F). The majority (89% and 88%, respectively) of ASD-associated DEGs were downregulated 1 
(orange and red fractions in Fig. 3G, Suppl. Table 2), supporting the idea of CHD8 as an 2 
important positive regulator of neurodevelopmental, autism-associated genes (13, 14). 3 
 4 
To determine if CHD8 functions as a positive or negative regulator of gene expression, we 5 
identified genes most likely directly regulated by CHD8, using ChIP-seq data from Cotney et 6 
al.  (13). From the Cotney dataset, a consensus set of gene promoters with CHD8 recruitment 7 
in E17.5 embryonic mouse brain, human midfetal cortex, and neural progenitor contexts was 8 
defined.  This gene list was compared to the list of differentially expressed genes in Chd8 9 
hypomorphs. This analysis revealed that the majority of DEGs were not identified in the 10 
consensus CHD8 ChIP-seq dataset (blue and orange fractions in Fig. 3G), suggesting that most 11 
transcriptional changes are induced by indirect effects. This is consistent with previous 12 
observations and the prevailing view that CHD8 regulates the expression of many other 13 
chromatin and epigenetic modifiers (13, 14).  DEGs with CHD8 localisation to their promoters 14 
in the Cotney data (red and purple fractions in Fig. 3G), were present in both up- and down 15 
regulated gene sets, suggesting that CHD8 can function as both an activator and repressor of 16 
these genes during cortical development. 17 
 18 
To identify potential transcriptional co-regulators and DNA-binding factors that may cooperate 19 
with CHD8 during embryonic cortical development, Gene Set Enrichment Analysis  was 20 
performed using the “ENCODE and ChEA Consensus TFs from ChIP-X” database in Enrichr 21 
(36). This analysis revealed an over-representation of E2F (E2F4, E2F6 and E2F1) targets in 22 
the upregulated genes (Suppl. Fig. 4, Suppl. Table 2). E2Fs compose a family of transcription 23 
factors with important roles in DNA replication, cell cycle progression and proliferation. CHD8 24 
has been previously shown to be involved in E2F-dependent transcriptional activation, and is 25 
 24 
necessary for recruitment of the “activator” E2F transcription factors E2F1 and E2F3 to G1/S 1 
transition promoters (37). Our findings suggest that CHD8 functions as a repressor of E2F-2 
regulated genes in the developing cortex and implicate increased progenitor proliferation as a 3 
potential mechanism for the brain hyperplasia in these mice. 4 
 5 
For downregulated genes, an over-representation of targets of REST (RE1-Silencing 6 
Transcription factor) and the Polycomb component Suz12 was seen (Suppl. Fig. 4, Suppl. 7 
Table 2). As Suz12 is essential for the activity and stability of the PRC2 complex, we asked if 8 
any of the DEGs are marked by the PRC2-repressive modification H3K27me3 in normal neural 9 
progenitor cells (38). The majority of DEGs that were  marked by  H3K27me3  in neural 10 
progenitors were downregulated in hypomorphic mice (pink fractions in Fig. 3H). Thus, some 11 
genes positively regulated by CHD8 are Polycomb targets in neural progenitors. Although 12 
further mechanistic studies will be required to test this, these findings are consistent with CHD8 13 
functioning as an antagonist of Polycomb repression as expected of a Trithorax family member. 14 
REST is a master regulator of neurodevelopment, has been shown to directly interact with 15 
CHD8, and is abnormally activated in Chd8 haploinsufficient mouse brain (15). Overlapping 16 
DEGs with REST ChIP-seq data (39), we found REST target genes predominantly amongst 17 
downregulated genes (orange and green fractions in Fig. 3H), supporting the notion that 18 
aberrant REST activation in Chd8-deficient embryonic brain may contribute to gene 19 
repression. Furthermore, 40% of the downregulated REST target genes are also marked by 20 
H3K27me3 in neural progenitor cells (green fractions in Fig. 3H), implying roles for both 21 
REST and Polycomb in the repression of these genes in Chd8 hypomorphs. 22 
 23 
To provide further insights into the biological processes affected by these gene expression 24 
changes, gene ontology analyses were performed. These identified a significant enrichment of 25 
 25 
cell cycle, DNA replication and repair genes in the upregulated genes in hypomorphs (Fig. 3I, 1 
Suppl. Table 3). Neurodevelopmental gene categories were enriched in the downregulated gene 2 
sets (Fig. 3I, Suppl. Table 3). 3 
 4 
Chd8 deficiency increases proliferation of cortical progenitors outside of the ventricular 5 
zone. 6 
To explore whether the increased expression of cell cycle and DNA replication genes in 7 
hypomorphs is indeed associated with increased progenitor proliferation, we immunolabelled 8 
progenitors in the G2/M phase of mitosis in coronal brain sections with an antibody against 9 
phosphohistone-3B (PH3B). No difference in the number of mitotic progenitors was observed 10 
in E12.5 Chd8+/- or Chd8neo/neo neocortices, compared to wildtype littermates (Suppl. Fig. 5A-11 
C). To determine if differences may arise later, we performed the same experiment at E14.5 12 
(Suppl. Fig. 5D,E). Again, no significant differences were seen in the numbers of proliferating 13 
ventricular progenitors (Suppl. Fig. 5F). Intriguingly, a significant increase in the proliferation 14 
of non-ventricular (or basal) progenitors was observed in Chd8neo/neo neocortices (Suppl. Fig. 15 
5G). No significant differences were observed in Chd8+/-or Chd8neo/- embryos (Suppl. Fig. 16 
5F,G), suggesting that the abnormal expansion of basal cortical progenitors only occurred 17 
within a restricted window of reduced CHD8 expression. 18 
 19 
To determine the identity of the non-ventricular progenitors that proliferated more in mild 20 
hypomorphs, we stained serial sections with antibodies to TBR2, a marker for intermediate 21 
progenitors, and PH3B (Fig. 4A). Counting these proliferating TBR2+ progenitors revealed a 22 
significant increase in the proliferation of these cells in Chd8neo/neo embryos, compared to 23 
controls (Fig. 4B). No significant changes in the number of proliferating TBR2+ progenitors 24 
was observed in other genotypes (Fig. 4B). Taken together, these experiments showed that 25 
 26 
TBR2+ intermediate progenitors accounted for the increased non-ventricular proliferation 1 
observed in Chd8neo/neo embryos. 2 
 3 
Our data suggests that TBR2+ intermediate progenitors might be particularly sensitive to 4 
reduced Chd8 expression. To find if Chd8 deficiency directly impacts gene regulation in these 5 
cells, we sorted TBR2+ and PAX6+ progenitors from E14.5 Chd8+/+,Chd8+/- and Chd8neo/neo 6 
neocortices by FACS and compared gene expression by qRT-PCR.  We selected two genes 7 
identified in our RNA-seq analysis that are upregulated in Chd8neo/neo mice, Pim1, a gene 8 
functionally linked to progenitor cell proliferation (40) and Axin2, a direct transcriptional target 9 
and feedback antagonists of WNT-b-catenin signalling (41). Both Pim1 and Axin2 were 10 
significantly upregulated in Chd8-deficient TBR2+, but not PAX6+ progenitors, with Axin2 11 
showing a clear Chd8 dosage-sensitive effect (Suppl. Fig 6B,C). Together, these findings show 12 
that Chd8 deficiency impacts the expression of specific genes linked to neural progenitor 13 
proliferation and fate specifically in TBR2+ intermediate progenitors. The gene expression 14 
changes in Chd8+/-  embryos may not be sufficient to increase the proliferation of these 15 
progenitors, or may have consequences at later stages of development. 16 
  17 
Next, we sought to identify the potential causes of cortical hypoplasia in severe hypomorphs 18 
(Suppl. Fig. 2E,G). We did not detect any reduction in cortical progenitor proliferation at E14.5 19 
in these mutants (Fig. 4B). Comparing gene ontology analyses between mild and severe 20 
hypopmorphs (Suppl. Fig. 7 and 8; Suppl. Table 3), revealed a slight increase in the number of 21 
p53-regulated genes and ribosomal genes like Rpl26 that can augment p53 mRNA translation 22 
(42) in severe hypomorphs, raising the possibility that progenitors may be more prone to 23 
apoptosis in these mice. Indeed, cleaved caspase 3 (CC3) immunostaining revealed a small 24 
increase in the numbers of apoptotic cells in Chd8neo/- embryos compared to Chd8neo/neo and 25 
 27 
control embryos (Fig. 4C-F), suggesting that increased cell death may be responsible for the 1 
brain hypoplasia in the severe hypomorphs. Thus, reducing CHD8 levels below 15% of 2 
wildtype, appeared to reveal another threshold below which p53-regulated genes become 3 
derepressed with an apparent impact on cell survival.  4 
 5 
CHD8 expression is essential for repression of p53 target genes in early embryonic 6 
neocortex. 7 
As the brain phenotype and effects on p53-regulated genes and apoptosis in severe hypomorphs 8 
were subtle, we decided to explore the consequences of complete CHD8 loss (0%), by 9 
conditional deletion of Chd8 in early neural progenitors. Sox1-cre-mediated deletion (Fig. 5A-10 
B, Suppl. Fig. 9) of loxP-flanked (flox) exon 3 results in an early frameshift and termination 11 
of translation at amino acid 419, which is predicted to produce a protein that lacks all functional 12 
domains and results in a Chd8-null allele as shown previously in Chd8+/- mice (18). 13 
 14 
The pan-neuronal, conditional deletion of Chd8 by Sox1-cre (Fig. 5B, Suppl. Fig. 9) resulted 15 
in pronounced brain hypoplasia in homozygous conditional knockout (cKO) embryos, 16 
compared to controls (Ctrl, Chd8flox/flox (Chd8f/f)) (Fig. 5C,D). Neocortical hypoplasia, with the 17 
maintenance of some subcortical brain structures was evident upon histological analysis of 18 
E18.5 embryos (Fig. 5C’,D’). To identify the origin of these defects, cKO embryos were 19 
examined at earlier stages of development. Telencephalic hypoplasia with markedly thinner 20 
neuroepithelium was evident in E12.5 cKO embryos when compared to controls (Fig. 5E-F’). 21 
Examination of E10.5 cKO embryos showed telencephalic vesicles of near-normal size with 22 
neuroepithelia that were slightly thinner than controls (Fig. 5G-H’), suggesting that CHD8 is 23 
essential for expansion of the pallium from early embryonic development. 24 
 25 
 28 
To identify the potential causes of this striking phenotype, we performed RNA-seq at the onset 1 
of the phenotype. RNA-seq analysis identified 2032 DEGs in E10.5 cKO telencephalic vesicles 2 
compared to controls (Fig. 6A, Suppl. Table 4). KEGG pathway mapping of all dysregulated 3 
DEGs identified the p53 pathway as the most significantly affected (Fig. 6B, Suppl. Fig. 10). 4 
Interestingly, GO analysis identified cell cycle as the most dysregulated bioprocess (Suppl. 5 
Table 4), with a slight majority of genes within this category downregulated (60 out of 111). 6 
Quantitative RT-PCR (qRT-PCR) confirmed significant upregulation of multiple p53-7 
regulated genes (Fig. 6C). Furthermore, genes normally upstream of p53, Atr and Atm, and 8 
Trp53 (the gene encoding p53 itself) were not affected by Chd8 deletion (Fig. 6C), consistent 9 
with a role for CHD8 in directly repressing p53 target genes (10).  10 
 11 
To ask if increased p53 pathway activity was responsible for the cKO phenotype, we reduced 12 
p53 gene expression in the neuronal lineage to test if this can reduce the severity or incidence 13 
of phenotypic abnormalities. Neocortical hypoplasia was partially rescued in Sox1-14 
Cre;Chd8f/f;Trp53f/+ (conditional knockout p53 heterozygous, cKO-p53het) embryos (Fig. 15 
6D), providing strong genetic evidence that this phenotype was caused by elevated p53 16 
signaling. A substantial increase in apoptosis was observed in the cKO embryos (Fig. 17 
6E,F,H,I). The number of apoptotic cells was significantly reduced in the pallium of cKO-18 
p53het embryos, compared to cKO embryos (Fig. 6F-I). We also noted the presence of certain 19 
cell cycle inhibitors amongst genes upregulated in the cKO (e.g. p21/CDKN1A)(Fig. 6C). 20 
Therefore, we investigated neural progenitor proliferation. Quantification of PH3B+ cells in 21 
the ventricular zone of the neocortex confirmed a strong reduction in cell proliferation in cKO 22 
embryos (Fig. 6J,J’,K,K’,M). Cell proliferation was slightly increased in cKO-p53het embryos 23 
compared to cKO embryos (Fig. 6L,L’,M), consistent with only a partial rescue of neocortical 24 
 29 
size in these animals (Fig. 6D). The visualisation of proliferating BrdU+ cells in the same 1 
sections appear to support this conclusion (Fig. J-L’). 2 
 3 
To determine if neuronal differentiation was affected in these mutants, we immunostained for 4 
Doublecortin (DCX). DCX+ cells were present in the preplate (pp) at the pial surface in all 5 
control embryos (n=3/3; Fig. 6N,N’). Ectopic clusters of DCX+ cells were visible throughout 6 
the neural tube of all cKO embryos (n=4/4), including the ventricular zone (Fig. 6O,O’), 7 
suggesting a precocious and disorganised differentiation of progenitors compared to controls 8 
(p=0.029, Fisher’s exact test). DCX+ cell positioning was normalised in all cKO-p53het 9 
embryos (n=4/4; Fig. 6P,P’) indicating a significant rescue of this phenotype compared to cKO 10 
embryos (p=0.029, Fisher’s exact test). 11 
 12 
Taken together, these data identify CHD8 as an essential repressor of p53 pathway activation 13 
during neocortical development. CHD8 loss leads to increased apoptosis, reduced neural 14 
progenitor proliferation and precocious cell differentiation during early embryonic 15 
development, resulting in severe neocortical hypoplasia by the end of gestation.  16 
 30 
Discussion 1 
Human genetic studies have identified heterozygous, likely gene disrupting mutations in CHD8 2 
as a possible cause of ASD and macrocephaly. Chd8 heterozygous mice have been generated 3 
by several groups, but these mice were found to exhibit relatively subtle brain overgrowth (15-4 
17, 19). Observations of relatively small transcriptional changes in the mid-gestation Chd8+/- 5 
mouse brain appeared at odds with the many genes dysregulated upon Chd8 knockdown in 6 
progenitor cell lines and after in utero electroporation (13, 14, 20). Together, these studies led 7 
us to explore whether different sensitivities to reduced CHD8 dosage might account for some 8 
of these inconsistencies. A comparison of brain size, gene expression and neural progenitor 9 
fate in a mouse Chd8 allelic series yielded several key findings: 1) A small additional reduction 10 
in Chd8 expression in mild hypomorphs compromised the capacity of neural progenitor cells 11 
to maintain stable expression of over 2000 genes in the mid-embryonic neocortex, which 12 
included over 140 ASD-associated genes; 2) CHD8 has a key role in limiting the expansion of 13 
TBR2+ intermediate progenitors, a population particularly important for human cortical 14 
development; 3) A gradual reduction in CHD8 expression can have non-linear effects on gene 15 
expression and brain growth (Fig. 7). In addition to the precipitous gene expression changes in 16 
mild hypomorphs, we observed brain hyperplasia in Chd8+/- and Chd8neo/neo mice, but brain 17 
hypoplasia in severe hypomorphs and conditional knockouts (Fig. 7). Together, these findings 18 
indicate that CHD8 levels need to be tightly regulated during development and that the 19 
interpretation of experimental manipulations that involve Chd8 knock-down should consider 20 
these non-linear, threshold effects. 21 
 22 
CHD8 as a phenotypic capacitor 23 
It has been posited previously that ASD-associated chromatin remodelling factors may act as 24 
phenotypic capacitors, buffering against perturbations to normal development in order to 25 
 31 
maintain stable phenotypes (43). Heterozygosity for a capacitor is predicted to result in a loss 1 
of robustness, such that the cells are more susceptible to additional genetic and non-genetic 2 
risk factors. Our findings that over 2200 genes, many of which are ASD risk factors, became 3 
dysregulated by a small additional decrease in CHD8 dosage below 50%, supports the idea that 4 
some neurodevelopmental genes and processes may be close to a critical threshold in the Chd8 5 
heterozygous neocortex and therefore easily perturbed by small additional changes. It will be 6 
important to determine if specific ASD-associated CHD8 mutations in humans reduce CHD8 7 
function by more than 50% by dominant negative mechanisms, as our findings would predict 8 
these mutations to be significantly more pathogenic than purely haploinsufficient mutations. It 9 
is also important to consider that the C57BL/6 genetic background has been used for all Chd8 10 
heterozygous mouse studies so far. This background may be protective and more robust in the 11 
context of Chd8 haploinsufficiency, such that different, or more severe phenotypes may emerge 12 
on different genetic backgrounds. We report a significant effect of sub-haploinsufficient levels 13 
of Chd8 expression on the proliferation of intermediate progenitors in the E14.5 embryonic 14 
cortex. It will be of interest to determine if other cell types relevant to CHD8 function in the 15 
brain, like oligodendrocytes (44), exhibit similar Chd8 gene dosage sensitive responses. 16 
 17 
CHD8 regulates the proliferation of non-ventricular cortical progenitors 18 
Our findings raise the possibility that brain development in human and mouse differ in 19 
sensitivity to a similar reduction in CHD8 function, such that CHD8 heterozygosity may cause 20 
more pronounced changes to brain growth and transcriptional regulation in the developing 21 
human brain. In this regard, fundamental differences in mouse and human brain development 22 
may result in CHD8 haploinsufficiency having more pronounced effects on human brain 23 
development. Comparative studies of gyrencephalic and lissencephalic animals have identified 24 
important differences in the capacity of non-ventricular progenitors to expand and 25 
 32 
subsequently contribute to cortical expansion. This population of progenitors consists of outer 1 
radial glia cells (oRGs), and TBR2-expressing intermediate progenitor cells (IPs) (45). In 2 
humans, oRGs are located in an expanded outer-subventricular zone (oSVZ) and are capable 3 
of asymmetric divisions that generate an oRG daughter cell, which maintains the pool of non-4 
ventricular progenitors, and an IP daughter cell that can undergo transit-amplifying divisions 5 
to expand and generate neuronal progeny (46). By contrast, mouse oRGs primarily undergo 6 
self-renewing, neurogenic divisions and populate a non-ventricular region lacking the distinct, 7 
expanded cytoarchitecture of the oSVZ typically seen in gyrencephalic species (47). 8 
Furthermore, mouse IPs likely possess a more limited capacity for self-renewal, as a majority 9 
of mouse IP divisions appear to generate two neuronal daughter cells (48, 49). Therefore, if 10 
CHD8 has an especially crucial role in regulating the expansion of TBR2+ progenitors also in 11 
the human brain, then it is possible that CHD8 deficiency in these cells could result in more 12 
pronounced phenotypes with regard to cortical over-growth and circuit disruption in humans. 13 
The lack of exacerbated ASD-linked behavioural phenotypes in Chd8neo/neo mice is consistent 14 
with this notion. 15 
 16 
Interestingly, we also note that Bernier et al. previously identified an enrichment for CHD8 17 
expression in areas outside the ventricular zone in human mid-fetal cortex (6), further 18 
supporting the idea that CHD8 may have an important role in regulating expansion of these 19 
cells. An analysis of neural progenitor subsets in CHD8-deficient human brain organoids 20 
should be a viable way to test this hypothesis. 21 
 22 
CHD8 is an essential repressor of p53 in neural progenitors 23 
One of the most striking non-monotonic effects of Chd8 efficiency reported here is brain 24 
hypoplasia in pan-neuronal Chd8 cKO mice, partly as a result of de-repression of the p53 25 
 33 
pathway in early neuroepithelial cells. This discovery identifies CHD8 as a critical repressor 1 
of p53 target gene activation in neural progenitors. Our findings suggest that very low levels 2 
of CHD8 are sufficient to repress p53 target genes and maintain neural progenitor self-renewal. 3 
One could speculate that the CHD8-dependent recruitment of histone H1 to p53 target genes 4 
to initiate a cooperative process of chromatin compaction (10), may require lower levels of 5 
CHD8 than another process that is dependent upon the constitutive recruitment of RNA 6 
polymerase (50) or other co-activating factors by CHD8 (Fig. 7). Our gene expression and 7 
apoptosis data suggest that CHD8 protein levels in Chd8neo/- embryos were close to this critical 8 
threshold. Interestingly, Cotney et al. also reported p53 signaling as one the most dysregulated 9 
pathways upon CHD8 knock-down in human neural stem cells (13). However, other studies in 10 
human cell lines have not demonstrated the same changes, including an in vitro knock-down 11 
of CHD8 to 20-25% of control levels in human SK-N-SH neural progenitor cells (51). 12 
Intriguingly, CHD8, and its family member CHD7, also maintains the survival of 13 
oligodendrocyte precursors by inhibiting the p53 pathway, although this appears to be 14 
primarily mediated via direct repression of the p53 gene (52). Together, these findings suggest 15 
that transcriptional responses to reduced CHD8 levels are highly context-dependent and may 16 
help shed light on reports that Chd8 knock-down in utero led to reduced proliferation and 17 
enhanced differentiation of neural progenitor (20). 18 
 19 
Behavioural phenotypes in Chd8-deficient mice.  20 
A number of Chd8+/- mouse models have been reported. Given the strong association between 21 
CHD8 mutations and ASD in humans, one might have expected these mice to exhibit robust, 22 
ASD-like behaviours. However, that is not the case, a finding not that surprising if one takes 23 
into account the pronounced differences in brain size and behaviour between these species. 24 
Nevertheless, we tested whether mice with more pronounced brain and gene expression 25 
 34 
phenotypes exhibit more pronounced behavioural phenotypes. With the possible exception of 1 
anxiety, the behavioural phenotypes of Chd8+/- and hypomorphic mice were remarkably 2 
similar, including robust, reproducible hypo-activity (18). 3 
 4 
Limitations 5 
As with all other Chd8 mouse studies so far, our models were on a C57BL/6 genetic 6 
background. Different, or more severe phenotypes may emerge on different genetic 7 
backgrounds. Given the significant postnatal lethality of Chd8 hypomorphic mice, we cannot 8 
exclude the possibility that the reason for not observing a particularly prominent exacerbation 9 
of behavioural phenotypes compared to heterozygous mice, may be that only mildly affected , 10 
surviving mice could be behaviourally phenotyped. Furthermore, unlike Chd8+/- mice, all 11 
Chd8neo/neo mice were born to Chd8neo/+ mothers, and the posibilty that differences in maternal 12 
care could account for subtle behavioural differences cannot be ruled out. Recent work have 13 
reported sexually dimorphic effects in another Chd8 model (19). We did not observe significant 14 
behavioural differences between males and females in our studies, and  the structural, 15 
molecular and developmental experiments reported here were performed with mixed sex 16 
samples. We therefore cannot rule out sex-specific effects in gene expression and perhaps even 17 
developmental phenotypes. Our findings identify an important role for the autism-associated 18 
factor CHD8 in controlling the proliferation of intermediate progenitors in the mouse 19 
neocortex. Our analysis of TBR2+ intermediate progenitors show a robust increase in the 20 
proliferation of these cells in Chd8 hypomorphs, but not Chd8+/- mice (Fig. 4), despite the latter 21 
showing significant alterations in gene expression (Suppl. Fig. 6). We cannot at this stage rule 22 
out the possibility that the dynamics of neural progenitor proliferation and differentiation differ 23 
in heterozygous and hypomorphic mice, and that intermediate progenitors over-proliferate also 24 
in Chd8+/- mice, but at a different developmental stage. A comprehensive, timed analysis of 25 
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TBR2+ progenitor fate will be required to test this possibility. We propose that CHD8 also 1 
regulates intermediate progenitor proliferation in human brain development, as indeed 2 
suggested by CHD8 expression studies (6), but studies on human cells are required to confirm 3 
this. Finally, we show that CHD8 represses p53-regulated genes and that p53 pathway 4 
hyperactivation in neuroepithelial cells that lack CHD8 is at least in part responsible for cellular 5 
phenotypes that can lead to cortical hypoplasia. These findings do not exclude the contribution 6 
of other pathways and cellular mechanisms to the hypoplasia phenotype. 7 
 8 
Conclusion 9 
In conclusion, our analysis of an allelic series of Chd8-deficient mice has identified clear non-10 
monotonic effects on gene expression and brain growth (Fig. 7). Recognition of the differing 11 
sensitivities of important cellular processes to CHD8 dosage and how small differences in 12 
CHD8 levels may lead to disproportionally large differences in phenotype is an important step 13 
in understanding the context-specific transcriptional roles of CHD8 in brain development. 14 
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Fig 1. Brain hyperplasia in Chd8 heterozygous and mild hypomorphic mice.  3 
A) Diagrammatic representation of the Chd8 allele containing the neo cassette between exons 4 
3 and 4. Exon 3 splicing to exon 4 yields a 150bp product (*) by RT-PCR using primers F and 5 
R. Aberrant splicing from exon 3 into the neo cassette yields a 246bp product (**) with primers 6 
F and neo.  7 
 42 
B) Quantitative RT-PCR of Chd8 transcripts in E9.5-E10.5 neocortices of indicated genotypes. 1 
C) Estimation of CHD8 protein levels in E12.5 neocortices by Western blot.  2 
D) High-resolution 7T structural MRI coronal images of Chd8+/- (n=12, all males, 22 weeks 3 
old) and Chd8neo/neo brains (n= 13, 8 males, 5 females, 16 weeks old), from posterior (top) to 4 
anterior (bottom) are shown. Absolute volumetric differences, relative to wildtype controls 5 
(n=30, 26 males, 4 females) are coloured according to the scale on the right. Some regions with 6 
enlarged volumes are labeled as follows: NCtx – neocortex, EcC – ectorhinal cortex, EnC – 7 
entorhinal cortex, HC – hippocampus, Cb – cerebellum.  8 
E) Absolute volumes relative to wildtypes are plotted for whole brain, neocortex and several 9 
other brain regions for the different genotypes as indicated. –FDR<0.15, *FDR<0.05, 10 
**FDR<0.01. See also Supplementary Table 1. MRI data from Chd8+/- and littermate control 11 



























Fig 2. Behavioural assessment of mild Chd8 hypomorphic mice.  4 
A-J) Behavioural assessments of a cohort of adult Chd8neo/neo (neo/neo, n= 24; 14 males, 10 5 
females, A-B, D-E, G-I or n=15; 10 males, 5 females, F,K or n=11; 6 males, 5 females, J) and 6 
Chd8+/+ (+/+, n=41; 26 males, 15 females, A-B, D-E, G-I or n=31, 21 males, 10 females, F,K 7 
or n=12; 6 males, 6 females, J) and pup Chd8neo/neo (neo/neo, n=10; 4 males, 6 females, C) and 8 
Chd8+/+ (+/+, n=12; 6 males, 6 females, C) mice. Chd8+/+ animals are illustrated using filled 9 
circles, dotted lines with grey bars and Chd8neo/neo animals with open triangles, solid lines and 10 
open bars. Apart from USVs (C), all other tests were conducted on young adults 6-14 weeks 11 
of age.  12 
 13 
A) Duration, in seconds, spent in each chamber of the three-chamber sociability test. All mice 14 
spent a significantly higher proportion of time in the chamber with the age- and sex- matched 15 
stranger con-specific mouse compared to the other chambers. Mean±SEM; ***<0.001 16 
(between-subjects ANOVA with student’s t-test as post-hoc analysis). 17 
B) Duration, in seconds, of social investigation over a three-minute period. Social investigation 18 
was defined as the combined total duration of head, body and anogenital sniffing of a 19 
conspecific mouse. Mean±SEM (between-subjects ANOVA). 20 
C) The mean number of ultrasonic vocalisations per minute on indicated postnatal days. 21 
Mean±SEM (repeated-measures ANOVA). 22 
D) Graph demonstrating the performance in the olfactory habituation/dishabituation test. 23 
Mean±SEM (repeated-measures ANOVA).  24 
 44 
E) The duration, in seconds, mice spent self-grooming during the 10-minute self-grooming test. 1 
Mean±SEM (between-subjects ANOVA).  2 
F) The average number of marbles buried, out of a maximum of 12, within a 30-minute period 3 
period. Mean±SEM; *<0.05, **<0.01 (repeated-measures ANOVA with student’s t-test as 4 
post-hoc analysis). 5 
G) Representative ethovision tracks of a Chd8neo/neo (neo/neo) and Chd8+/+ (+/+) animal 6 
plotting their movements during the 10-minute open field task.  7 
H)  The percentage of time spent in the centre of the open field arena during the 10-minute test. 8 
Mean±SEM; **p<0.01 (between-subjects ANOVA).  9 
I) The total distance travelled in the outer part of the open field arena over a 10-minute time-10 
period. Mean±SEM; ***<0.001 (between-subjects ANOVA).  11 
J) The total activity counts per 12h period on running wheels in the homecage during 7 days 12 
of dark-phase recording. Mean±SEM; *p<0.05 (repeated-measures ANOVA). 13 





Fig 3. Gene expression changes in Chd8-deficient neocortices. 2 
A) Volcano plot indicating all DEGs detected by DESeq2 in E12.5 Chd8+/- embryonic 3 
cortices. Each point represents an individual gene, and all heterozygote DEGs (FDR <0.05) 4 
are highlighted in red. n = 3 per condition. 5 
 46 
B) Volcano plot showing all DESeq2 detected DEGs in E12.5 neo/neo cortex. All 1 
differentially expressed genes (FDR <0.05) are highlighted in red. n = 3 per condition. 2 
C) Volcano plot of all DESeq2 detected DEGs in E12.5 neo/- cortex. All differentially 3 
expressed genes (FDR <0.05) are highlighted in red. n = 3 per condition.  4 
D) Heatmap of genes differentially expressed in neo/neo and neo/- embryos, indicating 5 
transformed relative expression levels in +/+, +/-, neo/neo and neo/- embryos. 6 
E) Mean normalised count of aligned RNA-seq reads for a selection of genes that were 7 
differentially expressed in the mild and severe hypomorphs. 8 
F) Venn diagram showing extent of overlap between neo/neo and neo/- DEGs and ASD 9 
associated genes obtained from the SFARI Human Gene database 10 
(https://gene.sfari.org/autdb/HG_Home.do, accessed March 2018).  11 
G) Breakdown of neo/neo and neo/- DEGs that are ASD associated, DEGs with known CHD8 12 
binding sites in E17.5 mouse neocortex, human mid foetal cortex and NSCs; and DEGs that 13 
are both ASD associated and have known CHD8 binding sites. Downregulated genes are 14 
denoted by a negative number. 15 
H) Breakdown of neo/neo and neo/- DEGs with H3K27me3 in neural progenitors, DEGs with 16 
known REST binding sites, and DEGs that have been shown to have both H3K27me3 in neural 17 
progenitors and REST binding sites. Downregulated genes are denoted by a negative number. 18 
I) Gene Ontology (GO) analysis of up and down-regulated neo/neo and neo/- DEGs under the 19 
“Biological Processes” category. The five most significant hits are shown for each set. See also 20 
Supplementary Table 3. 21 
  22 
  23 
 47 
1 
  2 
Fig 4. Increased proliferation of basal neural progenitors in Chd8neo/neo embryos.  3 
A) Immunohistochemistry to detect PH3B+ (blue) and TBR2+ (green) nuclei in coronal 4 
sections through the telencephalon of E14.5 embryos. White arrowheads indicate 5 
PH3B+/TBR2+ nuclei.White box is shown as zoomed inset containing a double positive cell. 6 
B) Quantification of TBR2+/PH3B+ cells per 100µm of neocortex in E14.5 embryos (+/+, 7 
n=20; neo/+, n=9; +/-, n=7; neo/neo, n=6; neo/-, n=8; Mean±SEM, *p<0.05, ***p<0.001, 8 
ANOVA followed by Tukey’s multiple comparisons test). 9 
C-E) Cleaved caspase 3 (CC3) immunostaining of dorsal neocortex of E14.5 embryos. Black 10 
arrows indicate CC3+ cells and black box in E highlights area shown in zoomed inset 11 
containing a CC3+ cell. Scale bar = 100µm. 12 
F) Relative quantification of CC3+ cells in neocortex of E14.5 Chd8 mutant embryos, 13 
normalised to respective wildtype littermates (+/+, n=17; neo/+, n=7; neo/neo, n=6; neo/-, 14 
n=11; Mean±SEM  **p<0.01). Embryos used in these experiments were from 8 different litters. 15 
 16 




Fig 5. Conditional deletion of Chd8 from the embryonic neuroepithelium results in severe 3 
hypoplasia of the telencephalon and neocortex 4 
A) Schematic representation of the wildtype (wt) mouse Chd8 gene (Chd8wt), targeting 5 
construct for homologous recombination in embryonic stem cells, the Chd8 targeted allele 6 
(Chd8neo), the Chd8 conditional allele after Flp-mediated excision of the neomycin resistance 7 
cassette (Chd8flox) and the Chd8null allele produced by Cre-mediated deletion of exon 3. Boxes 8 
represent exons, with exon 1 (Ex1) to 6 and 13 shown and exon 3 filled in black. The blue box 9 
represents a neomycin resistance cassette (neo), red triangles represent loxP sites and tan 10 
triangles frt sites. The long 9.45 kb (5’) homology arm is indicated in red and the short 4.4 kb 11 
(3’) homology arm in green in the targeting construct.  12 
B) X-gal staining of a Sox1-Cre;R26R embryo at E9.5 (left); and immunostaining for CHD8 13 
protein on Chd8flox/flox (Ctrl) and conditional knockout Sox1-Cre;Chd8flox/flox (cKO) E10.5 14 
neural tube (right). Scale bar = 50μm 15 
C,D) Wholemount images of E18.5 brains of a representative Ctrl and cKO embryo, anterior 16 
is to the right. Scale bar = 1mm 17 
E,F) Wholemount images of embryonic day 12.5 heads, anterior to the right. Scale bar = 1mm 18 
G,H) Wholemount images of  E10.5 embryos, anterior to the right.  19 
C’ –H’) Cresyl violet-stained frontal sections through brains as indicated in C-H above. Scale 20 
bars = 500μm (C’-D’) and 200μm (E’-H’). The following subcortical structures are labelled in 21 
Ctrl (C’) and cKO (D’) at E18.5: NCtx: Neocortex, mhN: medial habenular nucleus, vmt: 22 
ventral medial thalamic nucleus, amN: amygdaloid nucleus. Images are representative of at 23 
least 3 independent samples. 24 
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Fig 6. Repression of p53 target genes by CHD8 is necessary for normal brain growth. 2 
A) Volcano plot of RNA-seq data illustrating in red genes that are differentially expressed 3 
(FDR<0.05) in E10.5 cKO telencephalon, with p53 pathway genes labelled. 4 
B) Pathway enrichment analysis of differentially expressed genes, with the top KEGG pathway 5 
terms shown. See also Supplementary Table 4. 6 
C) qRT-PCR validation of a selection of p53 pathway genes identified by RNA-seq (n=4 for 7 
each condition. Mean±SEM; *p<0.05, ***p<0.001, student’s t-test). 8 
D) Wholemount brains from E18.5 Ctrl, cKO and cKO-p53het mice are shown, anterior to the 9 
top. Data are representative of 6 embryos per genotype. Scale bar = 1mm 10 
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E-G) Cleaved caspase 3 (CC3) immunohistochemistry (brown) on frontal sections through the 1 
telencephalon of E12.5 embryos. Scale bar = 200µm. 2 
H) Quantification of CC3+ cells/µm2 of the pallium in embryos of each genotype (Ctrl, n=4; 3 
cKO, n=3; cKO-p53het, n=3; Mean±SEM; *p<0.05, **p<0.01, ANOVA followed by Tukey’s 4 
multiple comparisons test). 5 
I) Quantification of CC3+ cells/µm2 of the subpallium (medial ganglionic eminence) in 6 
embryos of each genotype (Ctrl, n=4; cKO, n=3; cKO-p53het, n=3; Mean±SEM; *p<0.05, 7 
**p<0.01, ANOVA followed by Tukey’s multiple comparisons test). 8 
J-L) Immunohistochemistry to detect BrdU+ (red) and phospho-histone 3B (PH3B)+ nuclei in 9 
frontal sections through the telencephalon of E12.5 embryos. Scale bar = 100µm. 10 
J’-L’) Magnified images of the boxed neocortical regions in J-L, with the ventricular zone (vz) 11 
at the bottom and pial surface at the top. Scale bar = 25µm 12 
M) Quantification of PH3B+ cells/µm of neocortical ventricular surface (Ctrl, n=4; cKO, n=3; 13 
cKO-p53het, n=3; Mean±SEM; *p<0.05, **p<0.01, ANOVA followed by Tukey’s multiple 14 
comparisons test). 15 
N-P) Immunostaining of frontal E12.5 sections for DCX (green) to label differentiating 16 
neurons, with nuclei counterstained with Hoechst 33342. Scale bar = 200µm. 17 
N’-P’) Magnified images of N-P, with the ventricular zone (vz) at the bottom and pial surface 18 
(pp) at the top. Scale bar = 25µm. 19 
 20 




Fig 7. The non-monotonic relationship between CHD8 protein levels, gene expression 3 
and brain size. 4 
The effects of gradual reductions in CHD8 protein levels to ~50% (heterozygous), ~35% 5 
(mild hypomorph), ~10% (severe hypomorph) and 0% (conditional knockout) on the 6 
transcription of neurodevelopmental, cell cycle and p53-regulated genes and brain size are 7 
depicted. CHD8 appears to function primarily as a positive regulator of neurodevelopmental 8 
genes via recruitment to H3K4me3-modified (yellow ball) histones (gray spool), presumably 9 
via enabling the recruitment of key transcription factors (TF). A sharp reduction in the 10 
expression of many of these genes (arrow) is only observed in E12.5 neocortex when CHD8 11 
levels are reduced to below a threshold less than haploinsufficient levels. CHD8 appears to 12 
repress E2F-regulated cell cycle genes in this context, with significant induction only 13 
becoming evident at sub-haploinsufficient levels, although low expression increases (grey 14 
arrow) likely drives subtle increases in proliferation in the heterozygous state. Cell cycle 15 
genes are dysregulated in the opposite direction in the cKO, suggestive of non-monotonic 16 
effects (blue arrow). CHD8 can interact with p53 and histone 1 (H1), leading to stable 17 
heterochromatin formation and repression of p53 target genes. A few p53-regulated genes 18 
become activated in hypomorphic mice (grey arrow), but the majority remains fully repressed 19 
with de-repression only becoming evident upon complete CHD8 loss. Note the different 20 
CHD8 thresholds for different groups of genes (broken lines) and the non-monotonic effects 21 
on gene expression and over-all brain size. 22 




Supplementary Fig 1. CHD8 expression is reduced in Chd8+/-, Chd8neo/neo and Chd8neo/-  3 
embryo telencephalic vesicles at E12.5 4 
Whole cell lysate from telencephalic vesicles of indicated genotypes were subjected to 5 
western blot analysis using an anti-CHD8 antibody targeting the N-terminal portion of the 6 
protein, utilising either GAPDH (A) or β-actin as a loading control (B-D). Arrows indicate 7 
bands corresponding to target protein. The band just below is a non-specific band. Labels 8 
above individual wells indicate biological replicates used.  9 
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Supplementary Fig 2. Brain hypoplasia and unilateral anopthalmia in severe Chd8 2 
hypomorphic mice 3 
A-D) Representative wholemount images of brains from E18.5  severe Chd8 hypomorph 4 
(neo/-) and Chd8 heterozygous (+/-) embryos, with corresponding wildtype (+/+) littermate 5 
controls (A for B and C for D). 6 
E) Overlay of an E18.5 Chd8neo/- brain on to a littermate control brain. Note the smaller brain of 7 
the hypomorph. 8 
F) Overlay of an E18.5 Chd8+/- brain on to a littermate control brain. 9 
G) Absolute brain weights of wildtype control (+/+), Chd8+/- (+/-), and Chd8neo/- (neo/-) brains. 10 
Note the significantly smaller brain weights in Chd8neo/- mice compared to controls, and the 11 
trend towards heavier brains in Chd8+/- embryos. n = 17 (+/+),  n= 10 (+/-), n=8 (neo/-). Values 12 
plotted are mean ± SD. Scale bar = 2mm.  13 
H) Lateral view of heads of E18.5 Chd8neo/-  embryos with unilateral anopthalmia. White 14 
arrowheads indicate the presence of one eye on the left side of the head, whereas on the right 15 
side no apparent eye developed in the presumptive eye socket region. This was observed in 16 
two out of four Chd8neo/-  embryos examined for this phenotype, each from a different 17 
pregnancy.  18 
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Supplementary Fig 3. qRT-PCR validation of differential gene expression in E12.5 2 
neocortex.  3 
A-E) Relative expression levels for a selection of DEGs detected in the E12.5 RNA-seq as 4 
determined by qRT-PCR. cDNA for qRT-PCRs was reverse transcribed from total RNA 5 
extracted from E12.5 neocortex for the genotypes shown. Relative expression levels were 6 
calculated using the 2-∆∆CT method and Canx, Sdha and/or Ywhaz were used as endogenous 7 
control genes. (n = 3 per condition, Mean±SD, *p<0.05, **p<0.01, student’s t-test).  8 
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Supplementary Fig. 4. Analysis of transcription factor enrichment using Enrichr 2 
Putative regulatory transcription factors were determined with Enrichr using the “ENCODE 3 
and ChEA Consensus TFs from ChIP-X” database with all upregulated DEGs (top red 4 
panels) and downregulated DEGs (bottom blue panels) detected below a 0.05 FDR. The top 5 5 
most significant hits are shown. 6 
 56 
 1 
Supplementary Figure 5. Non-ventricular progenitor proliferation is increased at E14.5 2 
in Chd8neo/neo embryos. 3 
A,B) Immunostaining to detect PH3B+ nuclei (brown) in coronal sections through the 4 
telencephalon of E12.5 embryos of indicated genotypes. Scale bar = 100µm.  5 
C) Quantification of PH3B+ cells per 100µm of ventricular zone in E12.5 embryos (+/+, n=5; 6 
+/-, n=5; +/+, n=5; neo/neo, n=4; Mean±SEM,  student’s t-test).  7 
D,E,F,G) Immunostaining to detect PH3B+ nuclei (brown) in coronal sections through the 8 
telencephalon of E14.5 embryos of indicated genotypes. Inset shows high magnification view 9 
of boxed area. Scale bar = 100µm. 10 
F,G) Quantification of PH3B+ cells per 100µm in ventricular (F) or non-ventricular (G) areas 11 
of neocortex in E14.5 embryos (+/+, n=6; +/-, n=6; +/+, n=5; neo/neo, n=3; +/+, n=3; neo/-, 12 
n=4; Mean±SEM, **p<0.01, ANOVA followed by Tukey’s multiple comparisons test). 13 





Supplementary Figure 6. Gene expression in TBR2+ and PAX6+ neuronal progenitors 3 
in Chd8 mutant embryos.  4 
A) Schematic of FACS/RT-PCR workflow. The neocortex was dissected from E14.5 5 
embryonic brain and dissociated into single cell suspension. Cells were stained for TBR2 6 
(AlexaFluor 488) and PAX6 (PE) and TBR2+ and PAX6+ populations isolated by FACS. 7 
RNA was extracted from samples, reverse transcribed to cDNA and quantitative PCR was 8 
performed. qRT-PCR analysis confirms enriched expression of Tbr2 in Tbr2+ cells and 9 
enriched expression of Pax6 in Pax6+ cells, although the latter is not statistically significant, 10 
probably due to low Pax6 expression in early TBR2+ progenitors.  B,C) Fold expression 11 
changes in Pim1 (B) and Axin2 (C) in Chd8+/- and Chd8neo/neo  cells compared to WT cells are 12 





Supplementary Figure 7.  Functional Enrichment Analysis of differentially expressed 3 
genes (DEGs) in neo/neo embryos. 4 
DEGs (FDR <0.05) were subjected to KEGG pathway enrichment analysis (Top Panels), and 5 
screened for Gene Ontology terms in Molecular Function (Middle Panels) and Biological 6 
Process (Bottom Panels) categories using the DAVID knowledgebase. In each category, the 7 






Supplementary Fig 8. Functional Enrichment Analysis of differentially expressed genes 3 
(DEGs) in neo/- embryos. 4 
DEGs (FDR <0.05) were subjected to KEGG pathway enrichment analysis (Top Panels), 5 
screened for Gene Ontology terms in Molecular Function (Middle Panels) and Biological 6 
Process (Bottom Panels) categories using the DAVID knowledgebase. In each category, the 7 





Supplementary Fig 9. CHD8 is highly expressed during mid-embryonic stages and 3 
efficiently removed by recombination with Sox1-Cre. 4 
A-C’’) Immunostaining of E12.5, E11.5 and E10.5 brain sections with an anti-CHD8 antibody. 5 
Higher magnification images of dorsal cortex (boxed areas) are shown in A’-C”. Note the 6 
presence of nuclear CHD8 protein throughout the pallium and subpallium at E12.5 – E10.5 and 7 
higher levels of CHD8 immuno-staining in dorsal (A’-C’) compared to ventral pallium (A’’-8 
C’’). 9 
D-F’) Conditional pan-neuronal deletion of Chd8 results in widespread loss of CHD8 protein 10 
in all brain structures. Higher magnification images of dorsal cortex (boxed areas) are shown 11 
in D’-F’. Note the loss of CHD8 immunostaining in the neural tube, with unchanged expression 12 
in other tissues. The data is representative of 3 control and 3 cKO embryos of each stage. Scale 13 






Supplementary Fig 10. Diagram of the p53 pathway, with differentially expressed genes 4 
in the cKO highlighted.  5 
KEGG pathway mapping using DAVID of all differentially expressed genes revealed 6 
perturbed expression of 27 components of the p53 signalling pathway. Upregulated genes are 7 
boxed in red, downregulated genes in purple, and unchanged genes in blue. Solid lines 8 
indicate direct interactions whereas broken lines show indirect effects. Chd8 depletion 9 
resulted in more upregulated (22 genes) than downregulated (5 genes) p53 pathway 10 
components. The expression of p53 itself (green) was not significantly changed. This figure 11 
is adapted from KEGG map mmu04115 (53).  12 
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Supplementary Table 1: Raw MRI volumetric data, accompanies Fig. 1D,E. 15 
 16 
Supplementary Table 2: RNA-seq data from E12.5 neocortices, accompanies Fig. 3. 17 
 18 
Supplementary Table 3: Gene ontology and pathway analyses of E12.5 RNA-seq data, 19 
accompanies Fig. 3I. 20 
 21 
Supplementary Table 4: RNA-seq and gene ontology analysis of E10.5 cKO telencephalic 22 








Supplementary Table 5: Primer sequences 1 











Genotyping primer sequences: 13 
Gene  Forward Primer  Reverse Primer  
Chd8flox/ 
Chd8neo  GCCGAGGGGATGAGGATATTTAGG  GGTACATATGCCTTAAAAATCAGGCCCAG  
Chd8null  CCCACATCAAGTGGCTGTAA  GGTAGGGAAGCAGTGTCCAG  
p53flox  GGTTAAACCCAGCTTGACCA  GGAGGCAGAGACAGTTGGAG  
Cre  CCTGGAAAATGCTTCTGTCCG  CAGGGTGTTATAAGCAATCCC  
 14 
Neo allele splice variant primer sequences: 15 
Primer name  Sequence  
F  CAGAGGAGGAGGGTGAAAAGAAAC  
R GAGTTGTCAGACGATGTGTTACGC 
neo GATATTGCTGAAGAGCTTGGC  
 16 
Gene  Forward Primer  Reverse Primer  
Atr  GAATGGGTGAACAATACTGCTGG  TTTGGTAGCATACACTGGCGA  
Atm  TCTGTCCAGCAAAATCTCAAGG  CCCATGTAACAATAGCAGCCAA  
Mdm2  TGTCTGTGTCTACCGAGGGTG  TCCAACGGACTTTAACAACTTCA  
Ccng1  AGTCGGCCCATGATAATGGC  GTCCAACACACCCAAGATGC  
Trp53  GGGGAGGAGCCAGGCCATCA  CCGCGCCATGGCCATCTACA  
Pmaip1  TGGAGTGCACCGGACATAAC  AATCCTCCGGAGTTGAGCAC  
Chd8  CAGAGGAGGAGGGTGAAAAGAAAC  GAGTTGTCAGACGATGTGTTACGC  
Cdkn1a  TTGGAGTCAGGCGCAGATC  GACCGAAGAGACAACGGCA  
Kdm5b AAGCCAAGCTCTGTTCAGCAA GAAGGCAATCGTTCTTCTCACT 
Zcwpw1 GATGAAGAACCGGGCATTGTT GGCCTAGCTTAGATGTCCCCA 
Stxbp1 CATGAGAGCCATTGTCCCCA AGTGCTTTGTATCCAGCTTGTC 
Gapdh  AGGTCGGTGTGAACGGATTTG  TGTAGACCATGTAGTTGAGGTCA  
Ywhaz  GAAAAGTTCTTGATCCCCAATGC  TGTGACTGGTCCACAATTCCTT  
Axin2 CCCCACCTTGAATGAAGAAGAGG GCTGGATAACTCGCTGTCGTTG 
Pim1 GCGGCGAAATCAAACTCATC TGGTAGCGAATCCACTCTGG 
Otx1 TCTAACGTCCAATGCGGCTG GGTTGTTTGGAGGCGCAAAG 
Ier2 TGACTCTGTCGGTATGGAAGAT ACCTTGGCTGAGAGGTAGACC 
